Scilex Holding (SCLX) Cash from Operations (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Cash from Operations of 1107000.0 for Q1 2026, down 118.43% year-over-year from 6007000.0 in Q1 2025, and up 93.67% quarter-over-quarter from 17484000.0 in Q4 2025.
Scilex Holding (SCLX) Cash from Operations (2020 - 2026) Analysis & Trends
Scilex Holding's Cash from Operations history runs 7 years deep, the most recent figure standing at 1107000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 118.43% year-over-year to 1107000.0; the TTM figure through Mar 2026 stood at 3298000.0 (down 120.66% YoY), while the FY2025 annual figure was 3816000.0, down 80.28% from the prior year.
- Cash from Operations for Q1 2026 stood at 1107000.0, up from 17484000.0 in the prior quarter.
- The five-year high for Cash from Operations was 9391000.0 in Q1 2024, with the low at 17484000.0 in Q4 2025.
- The 5-year median for Cash from Operations is 2311000.0 (2024), against an average of 1171000.0.
- Peak annual rise in Cash from Operations reached 1884.07% in 2022, while the deepest fall reached 2136.1% in 2022.
- Scilex Holding's Cash from Operations stood at 725000.0 in 2022, then slumped by 643.45% to 5390000.0 in 2023, then soared by 147.01% to 2534000.0 in 2024, then sank by 789.98% to 17484000.0 in 2025, then surged by 93.67% to 1107000.0 in 2026.
- Business Quant data shows SCLX's Cash from Operations at 1107000.0 in Q1 2026, 17484000.0 in Q4 2025, and 8243000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.04 Bn | 633.28 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 470.61 Bn | 464.04 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 379.00 Bn | 371.86 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.78 Bn | 223.79 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 183.75 Bn | 180.57 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 160.91 Bn | 149.21 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.07 Bn | 101.90 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 40.64 Mn | -72.15 Mn | 3.97 Mn | -6.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.11 Mn |
| Mar 31, 2026 | -1.11 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Sep 30, 2025 | 8.24 Mn |
| Sep 30, 2025 | 8.24 Mn |
| Jun 30, 2025 | 7.05 Mn |
| Jun 30, 2025 | 7.05 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Dec 31, 2023 | -5.39 Mn |
| Dec 31, 2023 | -5.39 Mn |